Published in Clin Pharmacokinet on January 01, 2005
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol (2008) 1.06
Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int (2008) 0.99
Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) (2010) 0.99
Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med (2013) 0.92
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. Drug Des Devel Ther (2011) 0.90
Bisphosphonates pathway. Pharmacogenet Genomics (2011) 0.86
A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair (2010) 0.86
A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer (2009) 0.85
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One (2011) 0.85
Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants. Tissue Eng Part B Rev (2012) 0.84
Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr (2007) 0.84
Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab (2014) 0.83
Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos (2011) 0.83
Lip ulceration associated with intravenous administration of zoledronic acid: report of a case. Head Neck Pathol (2011) 0.82
Factors associated with atypical femoral fracture. Rheumatol Int (2015) 0.81
Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent (2014) 0.81
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis (2007) 0.81
Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions. J Bone Miner Metab (2015) 0.80
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. Drugs Aging (2016) 0.77
Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. PLoS One (2015) 0.77
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2006) 0.77
Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. J Transl Med (2015) 0.76
The biocompatibility of calcium phosphate cements containing alendronate-loaded PLGA microparticles in vitro. Exp Biol Med (Maywood) (2015) 0.76
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis. Clin Oral Investig (2016) 0.76
Zoledronic Acid-Induced Interface Dermatitis. Am J Dermatopathol (2015) 0.75
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab (2007) 0.75
A network modeling approach for the spatial distribution and structure of bone mineral content. AAPS J (2014) 0.75
Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study. Can J Vet Res (2011) 0.75
Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. Oncotarget (2016) 0.75
Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Ther Adv Musculoskelet Dis (2013) 0.75
Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury. Dig Dis Sci (2016) 0.75
Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.75
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology (2002) 2.49
Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab (2005) 2.05
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev (2005) 1.88
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res (2007) 1.76
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone (2010) 1.68
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol (2007) 1.58
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2004) 1.42
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res (2009) 1.41
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res (2005) 1.33
Prolonged bisphosphonate release after treatment in children. N Engl J Med (2007) 1.32
Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density. J Clin Endocrinol Metab (2015) 1.22
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol (2011) 1.21
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem (2002) 1.21
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem (2005) 1.12
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res (2011) 1.11
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res (2002) 1.06
Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res (2013) 1.06
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone (2012) 0.93
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res (2005) 0.92
Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging (2002) 0.91
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone (2008) 0.90
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone (2012) 0.86
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res (2002) 0.86
Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatol (2004) 0.86
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn (2010) 0.85
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn (2007) 0.84
Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet (2009) 0.84
Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. J Clin Endocrinol Metab (2008) 0.83
Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol (2011) 0.82
Medical treatment of hypercalcaemia. Hormones (Athens) (2009) 0.81
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs (2015) 0.81
Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res (2003) 0.81
Low-energy fractures of the humeral shaft and bisphosphonate use. J Bone Miner Res (2012) 0.80
Glucocorticoids are not always deleterious for bone. J Bone Miner Res (2010) 0.80
Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res (2002) 0.79
No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcif Tissue Int (2011) 0.79
Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study. J Bone Miner Res (2004) 0.78
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int (2005) 0.78
Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone (2004) 0.77
Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone (2003) 0.76
Bone diseases: bisphosphonates in osteoporosis--beyond 5 years. Nat Rev Rheumatol (2013) 0.76
In Memoriam: Olav Bijvoet 1928–2014. Bone (2014) 0.75